QoR-SCPB: Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06002152
Collaborator
(none)
160
2
27.4

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to learn whether a superficial cervical plexus block improves quality of recovery after thyroid surgery. Investigators will compare a superficial cervical plexus block with bupivacaine compared to an identical procedure performed saline placebo to see if there is a difference in quality of recovery on the first postoperative day.

The main question to answer is:

• Does a superficial cervical plexus block with bupivacaine compared to placebo improve quality of recovery in patients having thyroid surgery.

Participants will:
  • Fill out an initial preoperative survey

  • Be randomized to receive a superficial cervical plexus block with bupivacaine or saline placebo while under anesthesia before the surgery starts

  • Fill out a survey about recovery on the first day after surgery

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Thyroid surgery is associated with mild to moderate post-operative pain, with most patients requiring opioid pain medicine postoperatively. Nerve blocks, such as the superficial cervical plexus block, are an important component of pain control plans. Superficial cervical plexus blocks have been proven to decrease pain and reduce the need for opioid medications in thyroid surgery. However, previous studies were performed before it became common practice to administer a combination of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and steroids for thyroid surgery which also help with pain. Whether the superficial cervical plexus block improves pain control and quality of recovery in this context is unknown. This study aims to determine whether the superficial cervical plexus block has an impact on quality of recovery as measured by a survey called the Quality of Recovery-40 (QoR-40).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy: A Randomized Controlled Trial
Anticipated Study Start Date :
Sep 18, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bupivacaine

Participants randomized to this arm will receive 10ml of 0.25% bupivacaine on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.

Drug: Bupivacaine
After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.

Placebo Comparator: Placebo

Participants randomized to this arm will receive 10ml of saline on each side of the bilateral block. This will be done after induction of general anesthesia and prior to start of surgery.

Drug: Placebo
After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.

Outcome Measures

Primary Outcome Measures

  1. Quality of Recovery-40 (QoR-40) questionnaire score on postoperative day (POD) 1 [Up to 2 days]

    The QoR-40 is a widely used and well validated metric assessing postoperative quality of recovery. It includes 5 subsections investigating the dimensions of 'Emotional State' (9 questions), 'Physical Comfort' (12 questions), 'Psychological Support) (7 questions), 'Physical Independence' (5 questions), and 'Pain' (7 questions) for a total of 40 questions. The questions are scored on a 5-point Likert scale. Possible responses range from 1 = 'none of the time' to 5 = 'all of the time'. For negative items, the Likert scale is reversed. The individual scores are summed for the total score which can range from 40 points to 200 points. A higher score indicates better post-operative quality of recovery. Participants will be sent an electronic link to the survey via their email. They will complete the surveys privately from their own electronic devices. Investigators will then compare the changes in pre-operative vs POD 1 QoR-40 scores between the two groups.

Secondary Outcome Measures

  1. Opioid consumption postoperatively [Up to 2 days]

    This outcome will be measured in morphine milligram equivalents. The data will be obtained from electronic medical record (EMR) review. It will be measured from the start of the participant's post-anesthesia care unit (PACU) stay and through POD 1.

  2. Need for rescue analgesia prior to PACU discharge [approximately 4 hours]

    This outcome will be measured as "Yes" or "No". The data will be obtained from EMR review from the start of participant's PACU stay to end of participant's PACU stay

  3. Presence of nausea and/or vomiting in the PACU [approximately 4 hours]

    This outcome will be measured as "Yes" or "No". The data will be obtained from EMR review. It will be measured from the start of participant's PACU stay to end of participant's PACU stay.

  4. Need for rescue antiemetics in PACU [approximately 4 hours]

    This outcome will be measured as "Yes" or "No". The data will be obtained from EMR review. It will be measured from the start of participant's PACU stay to end of participant's PACU stay.

  5. PACU length of stay [approximately 4 hours]

    This outcome will be measured in minutes. The data will be obtained from EMR review. It will be measured from the start of participant's PACU stay to end of participant's PACU stay.

  6. Presence of patient reported side effects [up to 2 days]

    Participants will self-report any side effects that they experienced post-operatively from the start of their PACU stay and through POD 1.

  7. Patient reported quantity of other modes of analgesia, if any through POD 1 [up to 2 days]

    Participants will self-report any other modes of analgesia used post-operatively from the start of PACU stay and through POD 1.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18 years or older

  • American Society of Anesthesiologists Physical Status classification I-III

  • Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for the duration of the study

  • Scheduled for thyroid surgery

  • Access to smartphone device or computer with internet connection and has an email address

Exclusion Criteria:
  • Non-English speaking

  • American Society of Anesthesiologists Physical Status classification > III

  • Have an intolerance or contraindication to the medications involved in the study

  • Undergoing repeat thyroid surgery

  • Undergoing surgery with planned neck dissection

  • Plan for admission post-operatively

  • Positive pregnancy test on day of surgery (for participants with child-bearing potential)

  • Refusal to participate

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yale University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT06002152
Other Study ID Numbers:
  • 2000035991
First Posted:
Aug 21, 2023
Last Update Posted:
Aug 23, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2023